Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562214 | 1.00 | POLB (0.54) | POLBTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL562213 | 1.00 | POLB (0.54) | POLBTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL562210 | 1.00 | POLB (0.54) | POLBTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL562209 | 1.00 | POLB (0.54) | POLBTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL562419 | 0.90 | POLB (0.65) | POLBTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL562053 | 0.89 | POLB (0.67) | POLBTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL14982140 | 0.88 | POLB (0.54) | POLBTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL561920 | 0.87 | POLB (0.70) | POLBTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL561692 | 0.87 | POLB (0.70) | POLBTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL19497010 | 0.86 | POLB (0.54) | POLBTAS1R3TAS1R1TAS1R2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2154970-B1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2154970-B1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-8642633-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8404682-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8013003-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
| EP-2154970-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008143963-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | DRD2, DRD3, GAP43 | POLB 2847/4885TAS1R3 2130/4885TAS1R1 2305/4885 |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | DRD2, DRD3, GAP43 | POLB 2847/4885TAS1R3 2130/4885TAS1R1 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.